← Browse by Condition
Medical Condition

tumor solid

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 1, Phase 2, Phase 2

ClinicalMetric tracks all active clinical trials for tumor solid sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — tumor solid Clinical Trials

How many clinical trials are currently recruiting for tumor solid?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for tumor solid, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for tumor solid?
tumor solid research spans Phase 1 (4 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a tumor solid clinical trial?
Eligibility criteria for tumor solid trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
4
Phase 2
2
Top Sponsors
OncoNano Medicine, Inc. 1 trial
Shenzhen Ionova Life Sciences Co., Ltd. 1 trial
University of Pennsylvania 1 trial
Tao Zhang 1 trial
Centre Francois Baclesse 1 trial

Recruiting Clinical Trials

NCT06022029 Phase 1
Recruiting
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
Enrollment
168 pts
Location
United States, Austr...
Sponsor
OncoNano Medicine, Inc.
View Trial →
NCT04443088 Phase 1
Recruiting
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Enrollment
78 pts
Location
United States
Sponsor
Shenzhen Ionova Life Sciences ...
View Trial →
NCT04723810 Phase 1, Phase 2
Recruiting
TumorGlow Intraoperative Molecular Imaging (IMI)
Enrollment
500 pts
Location
United States
Sponsor
University of Pennsylvania
View Trial →
NCT06484556 Phase 1
Recruiting
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
Enrollment
9 pts
Location
China
Sponsor
Tao Zhang
View Trial →
NCT05943119 Phase 2
Recruiting
Phase II Study of Intensity Modulated Radiotherapy in Dose Painting for Sinus Carcinomas After Endoscopic Surgery
Enrollment
52 pts
Location
France
Sponsor
Centre Francois Baclesse
View Trial →

Related Conditions

triple negative breast cancer (1) diffuse large b cell lymphoma (1) follicular lymphoma (1) lymphoma non hodgkin (1) mantle cell lymphoma (1) bladder cancer (1) uveal melanoma recurrent (1) cervix cancer (1) carcinoma in situ (1) head and neck squamous cell carcinoma (1) skin cancer (1) metastatic cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology